Actively Recruiting
Neuromodulation in Patients With Neuropathic Pain and Depression.
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-07-01
60
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
High-frequency repetitive transcranial magnetic stimulation of the primary motor cortex has shown its effect on refractory neuropathic pain, and rTMS of the dorsolateral prefrontal cortex is commonly used for treatment-resistant depression. The treatment for patients suffering from neuropathic pain and depression, concomitantly, still needs to be studied, as there are some specificities in both symptoms and brain functional MRI.
CONDITIONS
Official Title
Neuromodulation in Patients With Neuropathic Pain and Depression.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Central or peripheral neuropathic pain
- Chronic pain lasting more than 6 months with intensity 4 or higher on a numerical scale
- Pain occurring daily or near-daily (at least 4 days per week)
- Incomplete relief from recommended first- and second-line neuropathic pain drugs
- Stable pain medication for at least one month with no planned changes during the study
- Diagnosed depressive episode according to DSM V criteria
- Neurologist has indicated motor cortex rTMS
- Ability to be followed for the entire study duration
- Provided informed consent and co-signed consent form
- Member or beneficiary of a social security scheme
You will not qualify if you...
- Industrial accident or ongoing litigation
- Contraindications to rTMS or MRI (including recent seismotherapy, epilepsy history, head trauma, neurosurgical lesion, intracranial hypertension, intracerebral metal clip, piercing, pacemaker, insulin pump, metal prosthesis)
- Pregnancy or breastfeeding
- Claustrophobia
- Drug or psychoactive substance abuse
- Neuropathic pain caused by progressive diseases (HIV, cancer, systemic disease)
- Presence of other pain more severe than neuropathic pain
- Unable to understand informed consent
- Unwilling or unable to stop prohibited treatments during the study
- Participation in another drug research protocol within 30 days prior to inclusion
- Deprived of liberty or under legal protection (guardianship, curatorship, safeguard of justice or family safeguard)
- Minor patient
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Saint-Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
R
Roland PEYRON, PhD
CONTACT
H
Hélène RAINGARD, CRA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here